DVAX
Price
$15.49
Change
-$0.02 (-0.13%)
Updated
Feb 5, 04:59 PM (EDT)
Capitalization
1.76B
14 days until earnings call
Intraday BUY SELL Signals
VTRS
Price
$14.30
Change
-$0.05 (-0.35%)
Updated
Feb 5, 04:05 PM (EDT)
Capitalization
16.54B
21 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DVAX vs VTRS

Header iconDVAX vs VTRS Comparison
Open Charts DVAX vs VTRSBanner chart's image
Dynavax Technologies
Price$15.49
Change-$0.02 (-0.13%)
Volume$48.84K
Capitalization1.76B
Viatris
Price$14.30
Change-$0.05 (-0.35%)
Volume$5.14K
Capitalization16.54B
DVAX vs VTRS Comparison Chart in %
View a ticker or compare two or three
VS
DVAX vs. VTRS commentary
Feb 06, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DVAX is a StrongBuy and VTRS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 06, 2026
Stock price -- (DVAX: $15.51 vs. VTRS: $14.36)
Brand notoriety: DVAX and VTRS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: DVAX: 128% vs. VTRS: 172%
Market capitalization -- DVAX: $1.76B vs. VTRS: $16.54B
DVAX [@Pharmaceuticals: Generic] is valued at $1.76B. VTRS’s [@Pharmaceuticals: Generic] market capitalization is $16.54B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DVAX’s FA Score shows that 0 FA rating(s) are green whileVTRS’s FA Score has 3 green FA rating(s).

  • DVAX’s FA Score: 0 green, 5 red.
  • VTRS’s FA Score: 3 green, 2 red.
According to our system of comparison, VTRS is a better buy in the long-term than DVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DVAX’s TA Score shows that 3 TA indicator(s) are bullish while VTRS’s TA Score has 4 bullish TA indicator(s).

  • DVAX’s TA Score: 3 bullish, 3 bearish.
  • VTRS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both DVAX and VTRS are a good buy in the short-term.

Price Growth

DVAX (@Pharmaceuticals: Generic) experienced а +0.19% price change this week, while VTRS (@Pharmaceuticals: Generic) price change was +10.72% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.85%. For the same industry, the average monthly price growth was -2.19%, and the average quarterly price growth was +12.81%.

Reported Earning Dates

DVAX is expected to report earnings on Feb 19, 2026.

VTRS is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.85% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VTRS($16.5B) has a higher market cap than DVAX($1.76B). VTRS has higher P/E ratio than DVAX: VTRS (236.20) vs DVAX (54.60). VTRS YTD gains are higher at: 15.341 vs. DVAX (0.845). DVAX has higher annual earnings (EBITDA): -25.65M vs. VTRS (-598.9M). VTRS has more cash in the bank: 1.16B vs. DVAX (648M). DVAX has less debt than VTRS: DVAX (285M) vs VTRS (14.7B). VTRS has higher revenues than DVAX: VTRS (14.1B) vs DVAX (331M).
DVAXVTRSDVAX / VTRS
Capitalization1.76B16.5B11%
EBITDA-25.65M-598.9M4%
Gain YTD0.84515.3416%
P/E Ratio54.60236.2023%
Revenue331M14.1B2%
Total Cash648M1.16B56%
Total Debt285M14.7B2%
FUNDAMENTALS RATINGS
DVAX vs VTRS: Fundamental Ratings
DVAX
VTRS
OUTLOOK RATING
1..100
2887
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
14
Undervalued
PROFIT vs RISK RATING
1..100
56100
SMR RATING
1..100
9396
PRICE GROWTH RATING
1..100
429
P/E GROWTH RATING
1..100
991
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (14) in the null industry is somewhat better than the same rating for DVAX (72) in the Biotechnology industry. This means that VTRS’s stock grew somewhat faster than DVAX’s over the last 12 months.

DVAX's Profit vs Risk Rating (56) in the Biotechnology industry is somewhat better than the same rating for VTRS (100) in the null industry. This means that DVAX’s stock grew somewhat faster than VTRS’s over the last 12 months.

DVAX's SMR Rating (93) in the Biotechnology industry is in the same range as VTRS (96) in the null industry. This means that DVAX’s stock grew similarly to VTRS’s over the last 12 months.

VTRS's Price Growth Rating (9) in the null industry is somewhat better than the same rating for DVAX (42) in the Biotechnology industry. This means that VTRS’s stock grew somewhat faster than DVAX’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is significantly better than the same rating for DVAX (99) in the Biotechnology industry. This means that VTRS’s stock grew significantly faster than DVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DVAXVTRS
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
66%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
58%
Momentum
ODDS (%)
Bearish Trend 2 days ago
68%
Bullish Trend 2 days ago
67%
MACD
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
70%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
66%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
63%
Advances
ODDS (%)
Bullish Trend 4 days ago
75%
Bullish Trend 4 days ago
71%
Declines
ODDS (%)
Bearish Trend 14 days ago
75%
Bearish Trend 9 days ago
66%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
59%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
DVAX
Daily Signal:
Gain/Loss:
VTRS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BCD33.200.10
+0.30%
abrdn Blmb AllCmdLDSK1Fr ETF
NEWTZ24.98N/A
N/A
NewtekOne
WLTG35.78-0.19
-0.53%
WealthTrust DBS Long Term Growth ETF
ZVOL10.30-0.10
-0.98%
1x Short VIX Mid-Term Futures Strategy ETF
CLM8.10-0.10
-1.22%
Cornerstone Strategic Value Fund

DVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, DVAX has been loosely correlated with TEVA. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if DVAX jumps, then TEVA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DVAX
1D Price
Change %
DVAX100%
+0.19%
TEVA - DVAX
62%
Loosely correlated
-3.56%
VTRS - DVAX
60%
Loosely correlated
+4.97%
IRWD - DVAX
58%
Loosely correlated
-6.37%
INDV - DVAX
47%
Loosely correlated
-3.13%
ALKS - DVAX
40%
Loosely correlated
-0.99%
More

VTRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VTRS has been closely correlated with AMRX. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if VTRS jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VTRS
1D Price
Change %
VTRS100%
+4.97%
AMRX - VTRS
70%
Closely correlated
+1.26%
ASRT - VTRS
67%
Closely correlated
-1.17%
COLL - VTRS
66%
Loosely correlated
+1.41%
TEVA - VTRS
66%
Loosely correlated
-3.56%
TLRY - VTRS
63%
Loosely correlated
-2.31%
More